E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Behaviours [F01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10001639 |
E.1.2 | Term | Alcoholism |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Does the action of the drug, mifepristone, in preventing the effects of the naturally released glucocorticoid hormone cortisol on the Type II glucocorticoid receptor reduce the cognitive deficits and/or the depression experienced by alcoholics? |
|
E.2.2 | Secondary objectives of the trial |
Does the drug, mifepristone, reduce the amount or frequency of relapse drinking in abstinent alcoholics? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
(i) diagnosis of alcohol dependence by DSM-IV for 5 years or more
(ii) male
(iii) aged between 18 and 60 years (inclusive)
(iv) willingness to provide informed consent
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria will be
(i) clinical diagnosis of a neuroendocrine disorder,
(ii) liver damage, determined by alanine aminotransferase (ALT) activity of more than 2.5 x normal range,
(iii) renal dysfunction, as determined by creatinine levels over 150 umol/L in plasma samples taken prior to admission to the Alcohol Unit
(iv) documented evidence of a psychotic disorder
(v) severe brain damage or severe mental impairment,
(vi) diagnosis of severe physical illness that would preclude participation (e.g. terminal illness),
(vii) documented evidence of current dependence on a substance other than alcohol or nicotine
(viii) inability to understand sufficient english to understand the information needed for the cognitive testing
(ix) female gender
(x) patients with Korsakoff's/Wernicke's syndromes (less than 2% in our Treatment Unit) will not be included because the cognitive deficits are considered to be permanent and due primarily to thiamine deficiency
(xi) porphyria
(xii) severe asthma uncontrolled by therapy
(xiii) cardiac disorders i.e. myocardial infarction, congestive cardiac failure or cardiomyopathy
(xvi) Has persistent high blood pressure (over 160 mmHg systolic and/or 100 mmHG diastolic on both of two readings at initial screening session)
(xv) medical history of diabetes
(xvi) known allergy to mifepristone
(xvii) owing to potential interactions with mifepristone, participants taking the following drugs will be excluded: ketoconazole, itraconazole, metronodazole, miconazole, erythromycin, clarithromycin, rifampin, rifabutin, norfloxacin, nelfinavir, ritonavir, saquinavir, zafirlukast, fluvoxamine, quinine, phenytoin, phenobarbital, primadone, carbamazepine, amiodarone, warfarin, corticosteroids or St John's Wort. Consumption of grapefruit juice is also contraindicated during mifepristone treatment
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Cognitive ability as measured by the CANTAB test battery
Depressive symptoms, as measured by the Beck depression scale |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
CANTAB - Days 13 and 20 inclusive and between Days 21 and 28 inclusive
Beck Depression Inventory (BDI-II) will record depressive symptoms every 7 days (± 2 days) for four weeks, starting one week after detoxification. The BDI-II will also be administered in Week 3, 4 and at the 3, 6 and 12 month follow up appointments. |
|
E.5.2 | Secondary end point(s) |
severity of the acute phase of alcohol withdrawal, alcohol craving and symptoms of protracted withdrawal including sleep disturbances |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The analysis on the data from the follow-up studies will be carried out when all the data from these have been collected, or in the case of difficulties in contacting for follow-up interviews, when the 12 month interval has passed for the last participant |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will be closed when all participants have made their final follow-up visit, the data have been entered into the database, all queries have been resolved and the database has been locked.
This definition allows time following the last visit of the last participant, to ensure that all data are thoroughly scrutinised and cleaned before being analysed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 14 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 14 |